

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names: List 53

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

### Dénominations communes internationales RECOMMANDÉES: Liste 53

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

### Denominaciones Comunes Internacionales RECOMENDADAS: Lista 53

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

<b>Latin</b> , English, French, Spanish: <i>Recommended INN</i>	<i>Chemical name or description; Molecular formula; Graphic formula</i>
<i>DCI Recommandée</i>	<i>Nom chimique ou description; Formule brute; Formule développée</i>
<i>DCI Recomendada</i>	<i>Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada</i>

**abataceptum**  
abatacept

1-25-oncostatin M (human precursor) fusion protein with CTLA-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimolecular (146→146')-disulfide

abatacept

(146→146')-disulfure bimoléculaire de [Gln<sup>151</sup>,Ser<sup>156</sup>,Ser<sup>162</sup>,Ser<sup>165</sup>,Ser<sup>174</sup>] (protéine de fusion entre le précurseur de l'oncostatine M humaine-(1-25)-peptide (séquence signal), la protéine 4 cytotoxique du lymphocyte-T humaine-[2-126]-peptide (partie extracellulaire de l'antigène CD152) et le peptide de 233 résidus fragment C-terminal de la chaîne lourde de l'immunoglobuline G1 humaine)

abatacept

1-25-oncostatina M (precursor humano) proteína da fusión con CTLA-4 (antígeno) (humano) proteína da fusión con inmunoglobulina G1 (fragmento humano de la pesada cadena), bimolecular (146→146')-disulfido

C<sub>3750</sub>H<sub>5872</sub>N<sub>982</sub>O<sub>1154</sub>S<sub>38</sub>

```

MGVLLTQRTL LSLVLALLFP SMASMAMHVA QPAVVLASSR
GIASFVCEYA SPGKATEVRV TVLRQADSQV TEVCAATYMM
GNETLFLDDS ICTGTSSGNQ VNLTIQGLRA MDTGLYICKV
ELMYPPPYL GIGNGTQIYV IDPEPCPDS QEPKSSDKTH
TSPPSPAPEL LGGSSVFLFP PKPKDTLMIS RTPEVTCVVV
DVSHEDPEVK FNWYVDGVEV HNAKTKPRE QYNSTYRVVS
VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR
EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN
GQPENNYKTT PPVLDSGGSF FLYSKLTVDK SRWQQGNVFS
CSVMHEALHN HYTQKSLSLS PGK

```

2

\* glycosylation site  
\* sites de glycosylation  
\* posiciones de glicosilación

**acotiamidum**


acotiamide

*N*-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]thiazol-4-carboxamide

acotiamide

*N*-[2-[bis(1-méthyléthyl)amino]éthyl]-2-[(2-hydroxy-4,5-diméthoxybenzoyl)amino]thiazol-4-carboxamide

acotiamida

*N*-[2-[bis(1-metiletil)amino]etil]-2-[(2-hidroxi-4,5-dimetoxibenzoil)amino]tiazol-4-carboxamida $C_{21}H_{30}N_4O_5S$ **alagebrium chloridum**

alagebrium chloride


4,5-dimethyl-3-(2-oxo-2-phenylethyl)thiazolium chloride

chlorure d'alagébrium

chlorure de 4,5-diméthyl-3-(2-oxo-2-phényléthyl)thiazolium

cloruro de alagebriu

cloruro de 4,5-dimetil-3-(2-fenil-2-oxoetil)tiazolio

 $C_{13}H_{14}ClNOS$ **alglucosidasum alfa**

alglucosidase alfa

human lysosomal prepro- $\alpha$ -glucosidase-(57-952)-peptide  
199-arginine-223-histidine variant

alglucosidase alfa

199-arginine-223-histidine variant du (57-952)-peptide de la prépro- $\alpha$ -glucosidase lysosomale humaine

alglucosidasa alfa

199-arginina-223-histidina variante del (57-952)-peptido de la prepro- $\alpha$ -glucosidasa lisosómica humana

$C_{4490}H_{6823}N_{1197}O_{1298}S_{32}$ 

```

QQGASRPGPR DAQAHPGRPR AVPTQCDVPP NSRFDCAPDK
AITQEQCEAR GCCYIPAKQG LQGAQMGGPW CFFPPSYPSY
KLEÑLSSEM GYTATLTRTT PTFFPKDILT LRLDVMMETE
NRLHFTIKDP ANRRYEVPLE TPRVHSRAPS PLYSVEFSEE
PFGVIVHRQL DGRVLLNTTV APLFFADQFL QLSTSLPSQY
ITGLAEHLSP LMLSTSWTRI TLWNRDLAPT PGANLYGSHP
FYLALEDGGS AHGVFLLNSN AMDVVLQPSP ALSWRSTGGI
LDVYIFLGPE PKSVMQYLD VVGYPFMPPY WGLGFHLCRW
GYSSTAITRQ VVENMTRAHF PLDVQWNDLD YMDSRRDFTF
NKDGFRDFPA MVQELHQGGR RYMMIVDPAI SSSGPAGSYR
PYDEGLRRGV FITNETGQPL IGKVWPGSTA FPDFTNPTAL
AWWEDMVAEF HDQVPFDGMW IDMNEPSNFI RGSDEGCPNN
ELENPPYVPG VVGGTQAAT ICASSHQFLS THYNLHNLYG
LTEAIAASHRA LVKARGTRPF VISRSTFAGH GRYAGHWTGD
VWSSWEQLAS SVPEILQFNL LGVPLVGADV CGFLGNTSEE
LCVRWTQLGA FYPFMRNHNS LLSLPQEPYS FSEPAQQAMR
KALTTRYALL PHLTYLFHQA HVAGETVARP LFLEFPKDSS
TWTVDHQLLW GEALLITPVL QAGKAEVTGY FPLGTWYDLQ
TVPIEALGSL PPPPAAPREP AIHSEGQWVT LPAPLDTINV
HLRAGYI IPL QGPGLTTES RQQPMALAVA LTKGGGEARGE
LFWDDGESLE VLERGAYTQV IFLARNNTIV NELVRVTSEG
AGLQLQKQTV LGVATAPQQV LSNQVPVSNF TYSPDTKVLD
ICVSLLMGEQ FLVSWC

```

\* glycosylation sites  
 \* sites de glycosylation  
 \* posiciones de glicosilación

**armodafinilum**


armodafinil

2-[(*R*)-(diphenylmethyl)sulfinyl]acetamide

armodafinil

(-)-2-[(*R*)-(diphénylméthyl)sulfinyl]acétamide

armodafinilo

(-)-2-[(*R*)-(difenilmetil)sulfinil]acetamida
 $C_{15}H_{15}NO_2S$ 


**bamirastinum**


bamirastine

2-[6-({3-[4-(diphenylmethoxy)piperidin-1-yl]propyl}amino)imidazo=[1,2-*b*]pyridazin-2-yl]-2-methylpropanoic acid

bamirastine

acide 2-[6-[[3-[4-(diphénylméthoxy)pipéridin-1-yl]propyl]amino]=imidazo[1,2-*b*]pyridazin-2-yl]-2-méthylpropanoïque

bamirastina

ácido 2-[6-[[3-[4-(difenilmetoxi)piperidin-1-il]propil]amino]imidazo=[1,2-*b*]piridazin-2-il]-2-metilpropanoico $C_{31}H_{37}N_5O_3$ **befetupitatum**


befetupitant

2-[3,5-bis(trifluoromethyl)phenyl]-*N*,2-dimethyl-*N*-[4-(2-methylphenyl)-6-(morpholin-4-yl)pyridin-3-yl]propanamide

béfétupitant

2-[3,5-bis(trifluométhyl)phényl]-*N*,2-diméthyl-*N*-[4-(2-méthylphényl)-6-(morpholin-4-yl)pyridin-3-yl]propanamide

befetupitant

2-[3,5-bis(trifluometil)fenil]-*N*,2-dimetil-*N*-[4-(2-metilfenil)-6-(morfolin-4-il)piridin-3-il]propanamida $C_{29}H_{29}F_6N_3O_2$ **belotecanum**

belotecan



(4*S*)-4-ethyl-4-hydroxy-11-[2-(isopropylamino)ethyl]-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-3,14(4*H*)-dione

bélotécan

(4*S*)-4-éthyl-4-hydroxy-11-[2-[(1-méthyléthyl)amino]éthyl]-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléine-3,14(4*H*)-dione

belotecán

(4*S*)-4-etil-4-hidroxi-11-[2-(isopropilamino)etil]-1,12-dihidro-14*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolina-3,14(4*H*)-diona

**carmoterolum**



carmoterol

8-hydroxy-5-[(1*R*)-1-hydroxy-2-[(1*R*)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]quinolin-2(1*H*)-one

carmotérol

8-hydroxy-5-[(1*R*)-1-hydroxy-2-[(1*R*)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]quinoléin-2(1*H*)-one

carmoterol

8-hidroxi-5-[(1*R*)-1-hidroxi-2-[(1*R*)-2-(4-metoxifenil)-propan-2-il]amino]etil]quinolin-2(1*H*)-ona**cetilistatum**



cetilistat

2-(hexadecyloxy)-6-methyl-4*H*-3,1-benzoxazin-4-one

cétilistat

2-(hexadécyloxy)-6-méthyl-4*H*-3,1-benzoxazin-4-one

cetilistat

2-(hexadeciloxi)-6-metil-4*H*-3,1-benzoxazin-4-ona**dasantafilum**

dasantafil


7-(3-bromo-4-methoxyphenylmethyl)-1-ethyl-8-[(1*R*,2*R*)-2-hydroxycyclopropyl]amino]-3-(2-hydroxyethyl)-3,7-dihydro-1*H*-purine-2,6-dione

dasantafil

7-(3-bromo-4-méthoxybenzyl)-1-éthyl-8-[(1*R*,2*R*)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyéthyl)-3,7-dihydro-1*H*-purine-2,6-dione

dasantafilo

7-(3-bromo-4-metoxibencil)-1-etil-8-[(1*R*,2*R*)-2-hidroxiciclopentil]amino]-3-(2-hidroxietyl)-3,7-dihidro-1*H*-purina-2,6-diona

$C_{22}H_{28}BrN_5O_5$ **deluceminum**


delucemine

3,3-bis(3-fluorophenyl)-*N*-methylpropan-1-amine

délucémine

3,3-bis(3-fluorophényl)-*N*-méthylpropan-1-amine

delucemina

3,3-bis(3-fluorofenil)-*N*-metilpropan-1-amina $C_{18}H_{27}N_5O_{21}P_4$ **denufosolum**

denufosol


2'-deoxycytidine(5')tetraphospho(5')uridine

dénufosol

2'-désoxycytidine(5')tétraphospho(5')uridine

denufosol

2'-desoxicitidina(5')tetrafosfo(5')uridina

 $C_{18}H_{27}N_5O_{21}P_4$ 

**depelestatum**

depelestat


human recombinant neutrophil elastase inhibitor, homologue of the second Kunitz domain of Inter-alpha-trypsin inhibitor light chain: [Glu<sup>285</sup>, Ile<sup>297</sup>, Phe<sup>300</sup>, Pro<sup>301</sup>, Arg<sup>302</sup>]AMB protein precursor-(285-340)-peptide (human)

dépelestat

[Glu<sup>285</sup>, Ile<sup>297</sup>, Phe<sup>300</sup>, Pro<sup>301</sup>, Arg<sup>302</sup>]précurseur de la protéine AMBP humaine-(285-340)-peptide, homologue du second domaine Kunitz de la chaîne légère de l'inhibiteur de l'Inter-alpha-trypsine, inhibiteur de l'élastase neutrophile

depelestat

[Glu<sup>285</sup>, Ile<sup>297</sup>, Phe<sup>300</sup>, Pro<sup>301</sup>, Arg<sup>302</sup>]precursor de la proteína AMBP humana-(285-340)-péptido, homólogo del segundo dominio Kunitz de la cadena ligera del inhibidor de la Inter-alfa-tripsina, inhibidor de la elastasa neutrófila

C<sub>282</sub>H<sub>412</sub>N<sub>74</sub>O<sub>75</sub>S<sub>6</sub>**dirlotapidum**

dirlotapide


*N*-[(1*S*)-2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]-1-methyl-5-[4'-(trifluoromethyl)biphenyl-2-carboxamido]-1*H*-indol-2-carboxamide

dirlotapide

*N*-[(1*S*)-2-(benzylméthylamino)-2-oxo-1-phényléthyl]-1-méthyl-5-[[[4'-(trifluorométhyl)biphényl-2-yl]carbonyl]amino]-1*H*-indole-2-carboxamide

dirlotapida

*N*-[(1*S*)-2-(bencilmetilamino)-2-oxo-1-feniletíl]-1-metil-5-[[[4'-(trifluorometil)bifenil-2-il]carbonil]amino]-1*H*-indol-2-carboxamida

C<sub>40</sub>H<sub>33</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>



**edaglitazonum**


edaglitazone

(5*RS*)-5-({4-[2-(5-méthyl-2-phényl-1,3-oxazol-4-yl)éthoxy]-1-benzothiophen-7-yl)méthyl}-1,3-thiazolidine-2,4-dione

édaglitazone

(5*RS*)-5-[[4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]-1-benzothiophén-7-yl]méthyl]thiazolidine-2,4-dione

edaglitazona

(5*RS*)-5-[[4-[2-(2-fenil-5-metiloxazol-4-il)etoxi]-1-benzotiofen-7-il]metil]tiazolidina-2,4-diona $C_{24}H_{20}N_2O_4S_2$ **eslicarbazepinum**


eslicarbazepine

(10*S*)-10-hydroxy-10,11-dihydro-5*H*-dibenzo[*b,f*]azepin-5-carboxamide

eslicarbazépine

(10*S*)-10-hydroxy-10,11-dihydro-5*H*-dibenzo[*b,f*]azépin-5-carboxamide

eslicarbazepina

(10*S*)-10-hidroxi-10,11-dihidro-5*H*-dibenzo[*b,f*]azepin-5-carboxamida $C_{15}H_{14}N_2O_2$ **exbivirumabum**

exbivirumab

immunoglobulin G, anti-(hepatitis B surface antigen) (human monoclonal 19.79.5 heavy chain), disulfide with human monoclonal 19.79.5  $\lambda$  chain, dimer

exbivirumab

immunoglobuline G, anti-(antigène de surface du virus de l'hépatite B) dimère du disulfure entre la chaîne lourde et la chaîne  $\lambda$  de l'anticorps monoclonal humain 19.79.5

exbivirumab

inmunoglobulina G, anti-(antígeno de superficie del virus de la hepatitis B) dímero del disulfuro entre la cadena pesada y la cadena  $\lambda$  del anticuerpo monoclonal humano 19.79.5 $C_{6416}H_{9924}N_{1732}O_{1982}S_{44}$

**fampronilum**


fampronil

2-[5-chloro-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-methyl-1*H*-pyrazol-4-yl]-1*H*-imidazole-4,5-dicarbonitrile

fampronil

2-[5-chloro-1-[2,6-dichloro-4-(trifluorométhyl)phényl]-3-méthyl-1*H*-pyrazol-4-yl]-1*H*-imidazole-4,5-dicarbonitrile

fampronilo

2-[5-cloro-1-[2,6-dicloro-4-(trifluorometil)fenil]-3-metil-1*H*-pirazol-4-il]-1*H*-imidazol-4,5-dicarbonitrilo $C_{16}H_6Cl_3F_3N_6$ **fidexabanum**


fidexaban

{[2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-[3-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)]phenoxy]pyridin-4-yl]methylamino}=acetic acid

fidexaban

acide {[2-(5-carbamimidoyl-2-hydroxyphénoxy)-3,5-difluoro-6-[3-(1-méthyl-4,5-dihydro-1*H*-imidazol-2-yl)]phénoxy]pyridin-4-yl]méthylamino]acétique

fidexabán

ácido {[2-(5-carbamimidoil-2-hidroxifenoxi)-3,5-difluoro-6-[3-(1-metil-4,5-dihidro-1*H*-imidazol-2-il)]fenoxi]piridin-4-il]metilamino]acético $C_{25}H_{24}F_2N_6O_5$ **fingolimodum**

fingolimod


2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol


fingolimod

2-amino-2-[2-(4-octylphényl)éthyl]propane-1,3-diol

fingolimod

2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol

 $C_{19}H_{33}NO_2$ 

[illegible]

**gantacurium chloridum**

gantacurium chloride


(1*R*,2*S*)-2-(3-[[[(2*Z*)-2-chloro-4-{3-[(1*S*,2*R*)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydroisoquinolinium-2-yl]propoxy}-4-oxobut-2-enoyl]oxy}propyl]-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolinium dichloride

chlorure de gantacurium

dichlorure de (1*R*,2*S*)-2-[3-[[[(2*Z*)-2-chloro-4-{3-[(1*S*,2*R*)-6,7-diméthoxy-2-méthyl-1-(3,4,5-triméthoxyphényl)-1,2,3,4-tétrahydroisoquinoléinio]propoxy}-4-oxobut-2-énoyl]oxy}propyl]-6,7-diméthoxy-2-méthyl-1-(3,4,5-triméthoxybenzyl)-1,2,3,4-tétrahydroisoquinoléinio]

cloruro de gantacurio

dicloruro de (1*R*,2*S*)-2-[3-[[[(2*Z*)-2-cloro-4-{3-[(1*S*,2*R*)-2-metil-6,7-dimetoxi-1-(3,4,5-trimetoxifenil)-1,2,3,4-tetrahidroisoquinolinio]=propoxi]-4-oxobut-2-enoil]oxi]propil]-2-metil-6,7-dimetoxi-1-(3,4,5-trimetoxibencil)-1,2,3,4-tetrahidroisoquinolinio]

C<sub>53</sub>H<sub>69</sub>Cl<sub>3</sub>N<sub>2</sub>O<sub>14</sub>**golimumabum**

golimumab

immunoglobulin G1, anti-(human tumor necrosis factor  $\alpha$ ) (human monoclonal CNTO 148  $\gamma$ 1-chain), disulfide with human monoclonal CNTO 148  $\kappa$ -chain, dimer

golimumab

immunoglobuline G1, anti-(facteur  $\alpha$  de nécrose tumorale humain) dimère du disulfure entre la chaîne  $\gamma$ 1 et la chaîne  $\kappa$  de l'anticorps monoclonal humain CNTO 148

golimumab

inmunoglobulina G1, anti-(factor  $\alpha$  de necrosis tumoral humano) dímero del disulfuro entre la cadena  $\gamma$ 1 y la cadena  $\kappa$  del anticuerpo monoclonal humano CNTO 148

C<sub>6530</sub>H<sub>10068</sub>N<sub>1752</sub>O<sub>2026</sub>S<sub>44</sub>**idronoxilum**

idronoxil


3-(4-hydroxyphenyl)-2*H*-chromen-7-ol

idronoxil

3-(4-hydroxyphényl)-2*H*-1-benzopyran-7-ol

idronoxilo

3-(4-hidroxifenil)-2*H*-1-benzopiran-7-ol

$C_{15}H_{12}O_3$ 

**imiglitazarum**  
imiglitazar


(4*E*)-4-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]=methoxy]imino]-4-phenylbutanoic acid

imiglitazar

acide (4*E*)-4-[[[4-[(5-méthyl-2-phényloxazol-4-yl)méthoxy]benzyl]=oxy]imino]-4-phénylbutanoïque

imiglitazar

ácido (4*E*)-4-[[[4-[(2-fenil-5-metiloxazol-4-il)metoxi]bencil]oxi]imino]-4-fenilbutanoico

 $C_{28}H_{26}N_2O_5$ 

**indacaterolum**  
indacaterol


5-[(1*R*)-2-[(5,6-diethyl-2,3-dihydro-1*H*-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1*H*)-one

indacatérol

5-[(1*R*)-2-[(5,6-diéthyl-2,3-dihydro-1*H*-indén-2-yl)amino]-1-hydroxyéthyl]-8-hydroxyquinoléin-2(1*H*)-one

indacaterol

5-[(1*R*)-2-[(5,6-dietil-2,3-dihidro-1*H*-inden-2-il)amino]-1-hidroxietyl]-8-hidroxiquinolin-2(1*H*)-ona

 $C_{24}H_{28}N_2O_3$ 

**indibulinum**  
indibulin



2-[1-(4-chlorophenylmethyl)-1*H*-indol-3-yl]-2-oxo-*N*-(pyridin-4-yl)acetamide

indibuline

2-[1-(4-chlorobenzyl)-1*H*-indol-3-yl]-2-oxo-*N*-(pyridin-4-yl)acétamide

indibulina

2-[1-(4-clorobencil)-1*H*-indol-3-il]-2-oxo-*N*-(piridin-4-il)acetamida

**ismomultinum alfa**


ismomultin alfa

47-261-Glycoprotein gp 39 (human clone CDM8-gp39 reduced)

ismomultine alfa

[290-isoleucine]glycoprotéine 39 constituant du cartilage humain (glycoforme alfa)

ismomultina alfa

fragmento 47-261 de la glicoproteina 39 constituyente del cartílago humano (variante [Arg<sup>124</sup>] producida por el clon humano CDM8-gp39)

```

YKLVCYTSW SQYREGDGSC FPDALDRFLC THIIYSFANI*
SNDHIDTWEW NDVTLYGMLN TLKNRNPNLK TLLSVGGWNF
GSQRFKIAS NTQSRRTFIK SVPPFLRTHG FDGLDLAWLY
PGRRDQHFHT TLIKEMKAEF IKEAQPGKKQ LLLSAALSAG
KVTIDSSYDI AKISQHLDFI SIMTYDFHGA WRGTTGHHSP
LFRGQEDASP DRFSNTDYAV GYMLRLGAPA SKLVMGIPTF
GRSFTLASSE TGVGAPISGP GIPGRFTKEA GTLAYYEICD
FLRGATVHRI LGQQVPYATK GNQWVGYYDDQ ESVKSKVQYL
KDRQLAGAMV WALDLDDFQG SFCGQDLRFP LTNAIKDALA
AT

```

\* glycosylation site

\* sites de glycosylation

\* posiciones de glicosilación

**lanimostimum**

lanimostim


4-221-colony-stimulating factor 1 (human clone p3ACSF-69 reduced)

lanimostim

facteur-1 de stimulation de colonie de macrophage humain-(4-221)-peptide (clone humain p3ACSF-69)

lanimostim

factor-1 de la estimulo de colonia de macrófago humano -(4-221)-péptido (clon humano p3ACSF-69)



```

[ SEYCSTM IGSGHLQSLQ RLIDSQMETs CQITFEFVDQ ]
EQLKDPVCYL KKAFLLVQDI MEDTMRFRDN TPNAIAIVQL
QELSLRLKSC FTKDYEEHDK ACVRTFYETP LQLEKVKNV
FNETKNLLDK DWNIFSKNCN NSFAECSSQD VVTKPDCNCL
YPKAIPSSDP ASVSPHQPLA PSMAPVAGLT WEDSEGTEGS
SLLPGEQPLH TVDPGSAKQR P ] 2

```

**lemuteporfinum**

lemuteporfin


dimethyl (2*RS*,2'*SR*)-8-ethenyl-13,17-bis=  
[3-(2-hydroxyethoxycarbonyl)-3-oxopropyl]-2,7,12,18-tetramethyl-  
2,2'-dihydrobenzo[*b*]porphyrin-2<sup>1</sup>,2<sup>2</sup>-dicarboxylate

lémutéporfine

*trans*-8-éthényl-13,17-bis[3-(2-hydroxyéthoxy)-3-oxopropyl]-  
2,7,12,18-tétraméthyl-2,2'-dihydrobenzo[*b*]porphyrine-  
2<sup>1</sup>,2<sup>2</sup>-dicarboxylate de diméthyle

lemuteporfina

*trans*-8-etenil-13,17-bis[3-(2-hidroxietoxi)-3-oxopropil]-  
2,7,12,18-tetrametil-2,2'-dihidrobenzo[*b*]porfirine-2<sup>1</sup>,2<sup>2</sup>-dicarboxylate  
de dimetilo

C<sub>44</sub>H<sub>48</sub>N<sub>4</sub>O<sub>10</sub>**lenalidomidum**

lenalidomide


(3*RS*)-3-(4-amino-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl)piperidine-  
2,6-dione

lénalidomide

(3*RS*)-3-(4-amino-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl)pipéridine-  
2,6-dione

lenalidomide

(3*RS*)-3-(4-amino-1-oxo-1,3-dihidro-2*H*-isoindol-2-il)piperidina-  
2,6-diona

C<sub>13</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>

and enantiomer  
et énantiomère  
y enantiómero

**lestaurtinibum**

lestaurtinib


(9*S*,10*S*,12*R*)-10-hydroxy-10-(hydroxymethyl)-9-methyl-2,3,9,10,11,12-hexahydro-1*H*-9,12-epoxydiindolo[1,2,3-*fg*:3',2',1'-*k*]pyrrolo=[3,4-*l*][1,6]benzodiazocin-1-one

lestaurtinib

(9*S*,10*S*,12*R*)-10-hydroxy-10-(hydroxyméthyl)-9-méthyl-2,3,9,10,11,12-hexahydro-9,12-époxy-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*k*]pyrrolo=[3,4-*l*][1,6]benzodiazocin-1-one

lestaurtinib

(9*S*,10*S*,12*R*)-10-hidroxi-10-(hidroximetil)-9-metil-2,3,9,10,11,12-hexahidro-9,12-epoxi-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*k*]pirrolo=[3,4-*l*][1,6]benzodiazocin-1-ona

C<sub>26</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>**libivirumabum**

libivirumab

immunoglobulin G, anti- (hepatitis B surface antigen)(human monoclonal 17.1.41 heavy chain), disulfide with human monoclonal 17.1.41  $\kappa$ -chain, dimer

libivirumab

immunoglobuline G, anti-(antigène de surface du virus de l'hépatite B) ; dimère du disulfure entre la chaîne lourde et la chaîne  $\kappa$  de l'anticorps monoclonal humain 17.1.41

libivirumab

inmunoglobulina G, anti-(antígeno de superficie del virus de la hepatitis B) ; dímero del disulfuro entre la cadena pesada y la cadena  $\kappa$  del anticuerpo monoclonal humano 17.1.41

C<sub>6598</sub>H<sub>10232</sub>N<sub>1788</sub>O<sub>2060</sub>S<sub>46</sub>**maraviroccum**

maraviroc

isopropyl, 4,4-difluoro-*N*-[(1*S*)-3-[(1*R*,3*s*,5*S*)-3-[3-methyl-5-(propan-2-yl)-4*H*-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexanecarboxamide


maraviroc

4,4-difluoro-*N*-[(1*S*)-3-[(1*R*,3*s*,5*S*)-3-[3-méthyl-5-(1-méthyléthyl)-4*H*-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phénylpropyl]=cyclohexanecarboxamide

maraviroc

4,4-difluoro-*N*-[(1*S*)-1-fenil-3-[(1*R*,3*s*,5*S*)-3-[3-isopropil-5-metil-4*H*-1,2,4-triazol-4-il]-8-azabíciclo[3.2.1]oct-8-il] propil]=ciclohexanocarboxamida



C<sub>29</sub>H<sub>41</sub>F<sub>2</sub>N<sub>5</sub>O

**mecaserminum rinfabas**  
mecasermin rinfabate

insulin-like growth factor I (human), complex with insulin-like growth factor-binding protein IGFBP-3 (human)

mécasermine rinfabate

facteur I de croissance humain analogue à l'insuline (mécasermine) lié à la [5-alanine]protéine-3 humaine se liant au facteur de croissance analogue à l'insuline (IGFBP-3 humaine)

mecasermina rinfabato

factor I del crecimiento humano semejante a la insulina (mecasermina) unida a la [5-alanina]proteína-3 humana unida con el factor de crecimiento similar a la insulina (IGFBP-3 humana)

C<sub>1231</sub>H<sub>1967</sub>N<sub>371</sub>O<sub>384</sub>S<sub>20</sub>

```

GPETLCGAEL  VDALQFVCGD  RGFYFNKPTG  YGSSSRRAPO
TGIVDECCFR  SCDLRRLEMY  CAPLKPAKSA

GASSAGLGVPV  VRCEPCDARA  LAQCAPPFAV  CAELVREPGC
GCCLTCALSE  GQPCGIYTER  CGSGLRCQPS  PDEARPLQAL
LDGRGLCVNA  SAVSRLRAYL  LPAPPAPGNA  SESEEDRSAG
SVESPSVSST  HRVSDPKFHP  LHSKIIIIKK  GHAKDSQRYK
VDYESQSTDT  QNFSSESKRE  TEYGPCRREM  EDTLNHLKFL
NVLSPRGVHI  PNCDKKGfYK  KKQCRPSKGR  KRGFVCVVDK
YGQPLPGYTT  KGKEDVHCYS  MQSK

```

**milataxelum**  
milataxel


1,10β-dihydroxy-9-oxo-5β,20-epoxy-3ζ-tax-11-ene-2α,4,7β,13α-tetrayl 4-acetate 2-benzoate 13-[(2*R*,3*R*)-3-(*tert*-butoxycarbonylamino)-3-(furan-2-yl)-2-hydroxypropanoate] 7-propanoate

milataxel

12b-acétate, 12-benzoate, 9-[(2*R*,3*R*)-3-[[[(1,1-diméthyléthoxy)carbonyl]amino]-3-(furan-2-yl)-2-hydroxypropanoate] et 4-propanoate de (2*aR*,4*S*,4*aS*,6*R*,7*E*,9*S*,11*S*,12*S*,12*bS*)-6,11-dihydroxy-4*a*,8,13,13-tétraméthyl-5-oxo-3,4,4*a*,5,6,9,10,11,12,12*a*-décahydro-7,11-méthano-1*H*-cyclodéca[3,4]benzo[1,2-*b*]oxète-4,9,12,12*b*(2*aH*)-tétrayle

milataxel

12b-acetato, 12-benzoato, 9-[(2*R*,3*R*)-3-[[[(1,1-dimetiletoxi)carbonil]amino]-3-(furan-2-il)-2-hidroxiopropanoato] y 4-propanoato de (2*aR*,4*S*,4*aS*,6*R*,7*E*,9*S*,11*S*,12*S*,12*bS*)-6,11-dihidroxi-4*a*,8,13,13-tetrametil-5-oxo-3,4,4*a*,5,6,9,10,11,12,12*a*-decahidro-7,11-metano-1*H*-ciclodeca[3,4]benzo[1,2-*b*]oxeto-4,9,12,12*b*(2*aH*)-tetraile

C<sub>44</sub>H<sub>55</sub>NO<sub>16</sub>**mirococeptum**  
mirococept


protein APT070 (synthetic human clone pET04-01 complement receptor type 1 short consensus repeat 1-3 fragment), (198→17')-disulfide with *N*-(tetradecanoyl)glycyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolyl-L-seryl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-prolylglycyl-L-aspartyl-L-cysteinamide

## mirococept

(238-17')-disulfure entre le [41-méthionyl]précurseur du récepteur de type 1 du complément-(41-238)-peptide et le (*N*-tétradécanoylglycyl)-L-séryl-L-séryl-L-lysyl-L-séryl-L-prolyl-L-séryl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-prolylglycyl-L-aspartyl-L-cystéinamide

## mirococept

(238-17')-disulfuro entre el [41-metionil]precursor del receptor de tipo 1 del complemento -(41-238)- péptido y el (*N*-tetradecanoilglicil)-L-seril-L-seril-L-lisil-L-seril-L-proil-L-seril-L-lisil-L-lisil-L-lisil-L-lisil-L-lisil-L-proililglicil-L-asartil-L-cisteinamida

C<sub>1054</sub>H<sub>1635</sub>N<sub>293</sub>O<sub>312</sub>S<sub>16</sub>

**paclitaxelum ceribas**  
paclitaxel ceribate


7β-[(2*RS*)-2,3-dihydroxypropoxycarbonyloxy]-1-hydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,10β,13α-tetraol 4,10-diacetate 2-benzoate 13-[(2*R*,3*S*)-3-benzamido-2-hydroxy-3-phenylpropanoate]

## céribate de paclitaxel

6,12b-diacétate, 12-benzoate, 4-[[[(2*RS*)-2,3-dihydroxypropoxy]=carboxylate] et 9-[(2*R*,3*S*)-3-(benzoylamino)-2-hydroxy-3-phénylpropanoate] de (2*aR*,4*S*,4*aS*,6*R*,7*E*,9*S*,11*S*,12*S*,12*aR*,12*bS*)-11-hydroxy-4*a*,8,13,13-tétraméthyl-5-oxo-3,4,4*a*,5,6,9,10,11,12,12*a*-décahydro-7,11-méthano-1*H*-cyclodéca[3,4]benzo[1,2-*b*]oxète-4,6,9,12,12*b*(2*aH*)-pentayle

## ceribato de paclitaxel

6,12*b*-diacétato, 12-benzoato, 4-[[[(2*RS*)-2,3-dihidroxiopropoxi]=carboxilato] y 9-[(2*R*,3*S*)-3-(benzoilamino)-3-fenilpropanoato-2-hidroxi] de (2*aR*,4*S*,4*aS*,6*R*,7*E*,9*S*,11*S*,12*S*,12*aR*,12*bS*)-11-hidroxi-4*a*,8,13,13-tetrametil-5-oxo-3,4,4*a*,5,6,9,10,11,12,12*a*-decahidro-7,11-metano-1*H*-ciclodeca[3,4]benzo[1,2-*b*]oxeto-4,6,9,12,12*b*(2*aH*)-pentailo

C<sub>51</sub>H<sub>57</sub>NO<sub>18</sub>**palosuranum**  
palosuran


1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea

## palosuran

1-[2-(4-benzyl-4-hydroxypipéridin-1-yl)éthyl]-3-(2-méthylquinoléin-4-yl)urée

## palosurán

1-[2-(4-bencil-4-hidroxiopiperidin-1-il)etil]-3-(2-metilquinolin-4-il)urea

C<sub>25</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub>

**panitumumabum**

panitumumab

immunoglobulin, anti-(human epidermal growth factor receptor)  
(human monoclonal ABX-EGF heavy chain), disulfide with human  
monoclonal ABX-EGF light chain, dimer

panitumumab

immunoglobuline, anti-(récepteur du facteur de croissance épidermal  
humain) dimère du disulfure entre la chaîne lourde et la chaîne  
légère de l'anticorps monoclonal humain ABX-EGF

panitumumab

inmunoglobulina, anti-(receptor del factor de crecimiento epidérmico  
humano) dímero del disulfuro entre la cadena pesada y la cadena  
ligera del anticuerpo monoclonal humano ABX-EGF

$$\text{C}_{6306}\text{H}_{9732}\text{N}_{1672}\text{O}_{1994}\text{S}_{46}$$
**pegamotecanum**

pegamotecan


$\alpha$ -{2-[(2*S*)-1-[[[(4*S*)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-  
1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl]oxy]-1-oxopropan-  
2-ylamino]-2-oxoethyl)- $\omega$ -(2-[(2*S*)-1-[[[(4*S*)-4-ethyl-3,14-dioxo-  
3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-  
4-yl]oxy]-1-oxopropan-2-ylamino]-2-oxoethoxy)poly(oxyethane-  
1,2-diyl)

pégamotécán

dérivé pégylé de la camptothécine obtenu par amidification entre le  
(2*S*)-2-aminopropanoate de (4*S*)-4-éthyl-3,14-dioxo-3,4,12,14-  
tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yle  
(L-alaninate de camptothécine) et le  $\alpha$ -(carboxyméthyl)-  
 $\omega$ -(carboxyméthoxy)poly(oxyéthylène)

pegamotecán

derivado pegilado de la camptotecina obtenido por amidificación  
entre el (2*S*)-2-aminopropanoato de (4*S*)-4-etil-3,14-dioxo-3,4,12,14-  
tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolín-4-ilo  
(L-alaninato de camptotecina) y el  $\alpha$ -(carboximetil)-  
 $\omega$ -(carboximetoxi)poli(oxietileno)

$$\text{C}_{50}\text{H}_{44}\text{N}_6\text{O}_{13} [\text{C}_2\text{H}_4\text{O}]_n$$
**pelitinibum**

pelitinib

(2*E*)-*N*-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-  
7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide

pélitinib

(2*E*)-*N*-[4-[(3-chloro-4-fluorophényl)amino]-3-cyano-  
7-éthoxyquinoléin-6-yl]-4-(diméthylamino)but-2-énamide

pelitinib


(2*E*)-*N*-[4-[(3-cloro-4-fluorofenil)amino]-3-ciano-7-etoxiquinolin-6-il]-  
4-(dimetilamino)but-2-enamida

**perflubutanum**

perflubutane

perflubutane


perflubutano



1,1,1,2,2,3,3,4,4,4-decafluorobutane

décafluorobutane



decafluorobutano

**perzinfotelum**

perzinfotel

perzinfotel

perzinfotel



[2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]=  
phosphonic acidacide [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-én-2-yl)éthyl]=  
phosphoniqueácido [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-il)etil]=  
fosfónico**prasugrelum**

prasugrel

prasugrel

prasugrel

5-[(1*RS*)-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-  
4,5,6,7-tetrahydrothieno[3,2-*c*]pyridin-2-yl acetateacétate de 5-[(1*RS*)-2-cyclopropyl-1-(2-fluorophényl)-2-oxoéthyl]-  
4,5,6,7-tétrahydrothiéno[3,2-*c*]pyridin-2-yleacetato de 5-[(1*RS*)-2-ciclopropil-1-(2-fluorofenil)-2-oxoetil]-  
4,5,6,7-tetrahidrotieno[3,2-*c*]piridin-2-ilo

**radafaxinum**



radafaxine

(2*S*,3*S*)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol

radafaxine

(+)-(2*S*,3*S*)-2-(3-chlorophényl)-3,5,5-triméthylmorpholin-2-ol

radafaxina

(+)-(2*S*,3*S*)-2-(3-clorofenil)-3,5,5-trimetilmorfolin-2-ol**ranirestatum**


ranirestat

(3*R*)-2'-(4-bromo-2-fluorobenzyl)spiro[pyrrolidine-3,4'-(1'*H*)-pyrrolo[1,2-*a*]pyrazine]-1',2,3',5(2'*H*)-tetrone

ranirestat

(-)-(3*R*)-2'-(4-bromo-2-fluorobenzyl)spiro[pyrrolidine-3,4'-(1'*H*)-pyrrolo[1,2-*a*]pyrazine]-1',2,3',5(2'*H*)-tétrone

ranirestat

(-)-(3*R*)-2'-(4-bromo-2-fluorobencil)espiro[pirrolidina-3,4'-(1'*H*)-pirrolo[1,2-*a*]pirazina]-1',2,3',5(2'*H*)-tetrona**regadenosonum**

regadenoson



1-(6-amino-9-β-D-ribofuranosyl-9*H*-purin-2-yl)-*N*-methyl-1*H*-pyrazole-4-carboxamide

régadénoson

1-(6-amino-9-β-D-ribofuranosyl-9*H*-purin-2-yl)-*N*-méthyl-1*H*-pyrazole-4-carboxamide

regadenosón

1-(6-amino-9-β-D-ribofuranosil-9*H*-purin-2-il)-*N*-metil-1*H*-pirazol-4-carboxamida

**reparixinum**



reparixin

(2*R*)-2-[4-(2-methylpropyl)phenyl]-*N*-methylsulfonylpropanamide

réparixine

(-)-(2*R*)-2-[4-(2-méthylpropyl)phényl]-*N*-(méthylsulfonyl)propanamide

reparixina

(-)-(2*R*)-2-[4-(2-metilpropil)fenil]-*N*-(metilsulfonyl)propanamida**retapamulinum**



retapamulin

(3*aS*,4*R*,5*S*,6*S*,8*R*,9*R*,9*aR*,10*R*)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3*a*,9-propanocyclopenta[8]annulen-8-yl[[[(1*R*,3*s*,5*S*)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate

rétapamuline

[[[(1*R*,3*s*,5*S*)-8-méthyl-8-azabicyclo[3.2.1]oct-3-yl]sulfanyl]acétate de (3*aS*,4*R*,5*S*,6*S*,8*R*,9*R*,9*aR*,10*R*)-6-éthényl-5-hydroxy-4,6,9,10-tétraméthyl-1-oxodécahydro-3*a*,9-propano-3*aH*-cyclopenta[8]annulén-8-yle

retapamulina

[[[(1*R*,3*s*,5*S*)-8-metyl-8-azabicyclo[3.2.1]oct-3-il]sulfanil]acetato de (3*aS*,4*R*,5*S*,6*S*,8*R*,9*R*,9*aR*,10*R*)-6-etenil-5-hidroxi-4,6,9,10-tetrametil-1-oxodecahidro-3*a*,9-propano-3*aH*-ciclopenta[8]anulen-8-ilo

**revaprazanum**


revaprazan

*N*-(4-fluorophenyl)-4,5-dimethyl-6-[(1*RS*)-1-methyl-3,4-dihydroisoquinolin-2(1*H*)-yl]pyrimidin-2-amine

révaprazan

*N*-(4-fluorophényl)-4,5-diméthyl-6-[(1*RS*)-1-méthyl-3,4-dihydroisoquinoléin-2(1*H*)-yl]pyrimidin-2-amine

revaprazán

*N*-(4-fluorofenil)-4,5-dimetil-6-[(1*RS*)-1-metil-3,4-dihidroisoquinolin-2(1*H*)-il]pirimidin-2-amina $C_{22}H_{23}FN_4$ **rilpivirinum**


rilpivirine

4-[[4-[(1*E*)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]pyrimidin-2-yl]amino]benzonitrile

rilpivirine

4-[[4-[[4-[(1*E*)-2-cyanoéthényl]-2,6-diméthylphényl]amino]pyrimidin-2-yl]amino]benzonitrile

rilpivirina

4-[[4-[[4-[(1*E*)-2-cianoetenil]-2,6-dimetilfenil]amino]pirimidin-2-il]amino]benzonitrilo $C_{22}H_{18}N_6$ **ritobegronum**


ritobegron

[4-(2-[[[(1*R*,2*S*)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid

ritobégron

acide [4-[2-[[[(1*S*,2*R*)-2-hydroxy-2-(4-hydroxyphényl)-1-méthyléthyl]amino]éthyl]-2,5-diméthylphénoxy]acétique

ritobegrón

ácido [4-[2-[[[(1*R*,2*S*)-1-hidroxi-1-(4-hidroxifenil)prop-2-il]amino]etil]-2,5-dimetilfenoxi]acético $C_{21}H_{27}NO_5$ 



**robenacoxibum**

robenacoxib


{5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]phenyl}acetic acid

robénacoxib

acide [5-éthyl-2-[(2,3,5,6-tétrafluorophényl)amino]phényl]acétique

robenacoxib

ácido [5-etil-2-(2,3,5,6-tetrafluoroanilino)fenil]acético

 $C_{16}H_{13}F_4NO_2$ **rostafuroxinum**


rostafuroxin

21,23-epoxy-24-nor-14 $\beta$ ,5 $\beta$ -chola-20,21-diene-3 $\beta$ ,14,17 $\alpha$ -triol

rostafuroxine

17-(furan-3-yl)-5 $\beta$ ,14 $\beta$ -androstane-3 $\beta$ ,14,17 $\alpha$ -triol

rostafuroxina

17-(furan-3-il)-5 $\beta$ ,14 $\beta$ -androstano-3 $\beta$ ,14,17 $\alpha$ -triol $C_{23}H_{34}O_4$ **selodenosonum**


selodenoson

1-[6-(cyclopentylamino)-9*H*-purin-9-yl]-1-deoxy-*N*-ethyl- $\beta$ -D-ribofuranuronamide

sélodénoson

1-[6-(cyclopentylamino)-9*H*-purin-9-yl]-1-désoxy-*N*-éthyl- $\beta$ -D-ribofuranuronamide

selodenosón

1-[6-(ciclopentilamino)-9*H*-purin-9-il]-1-desoxi-*N*-etil- $\beta$ -D-ribofuranuronamida $C_{17}H_{24}N_6O_4$ 

**taltobulinum**


taltobulin

(2*E*,4*S*)-4-[(2*S*)-*N*,3,3-trimethyl-2-[(2*S*)-3-methyl-2-(methylamino)-3-phenylbutanamido]butanamido]-2,5-dimethylhex-2-enoic acid

taltobuline

acide (2*E*,4*S*)-4-[[[(2*S*)-3,3-diméthyl-2-[[[(2*S*)-3-méthyl-2-(méthylamino)-3-phénylbutanoyl]amino]butanoyl]méthylamino]-2,5-diméthylhex-2-énoïque

taltobulina

ácido (2*E*,4*S*)-4-[(2*S*)-*N*,3,3-trimetil-2-[(2*S*)-3-metil-2-(metilamino)-3-fenilbutanamido]butanamido]-2,5-dimetilhex-2-enoico $C_{27}H_{43}N_3O_4$ **tandutinibum**


tandutinib

4-[6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl]-*N*-[4-(propan-2-yloxy)phenyl]piperazine-1-carboxamide

tandutinib

4-[6-méthoxy-7-[3-(pipéridin-1-yl)propoxy]quinazolin-4-yl]-*N*-[4-(1-méthyléthoxy)phényl]pipérazine-1-carboxamide

tandutinib

4-[6-metoxi-7-[3-(piperidin-1-il)propoxi]quinazolin-4-il]-*N*-[4-(1-metiletoxi)fenil]piperazina-1-carboxamida $C_{31}H_{42}N_6O_4$ **teglicarum**


teglicar

(3*R*)-3-[(tetradecylaminocarbonylamino]-4-(trimethylazaniumyl)=butanoate

téglicar

(3*R*)-3-[(tétradécylcarbamoyle)amino]-4-(triméthylammonio)butanoate

teglicar

(3*R*)-3-[(tetradecilcarbamoil)amino]-4-(trimetilamonio)butanoato $C_{22}H_{45}N_3O_3$ 

**telavancinum**

telavancin


(3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38*aR*)-3-(2-amino-2-oxoethyl)-10,19-dichloro-44-[[3-[[2-(decanyl amino)ethyl]amino]-2,3,6-trideoxy-3-*C*-methyl- $\alpha$ -*L*-lyxo-hexopyranosyl-(1 $\rightarrow$ 2)- $\beta$ -D-glucopyranosyl]oxy]-7,22,28,30,32-pentahydroxy-6-[(2*R*)-4-methyl-2-(methylamino)=pentanamido]-2,5,24,38,39-pentaexo-29-[[[(phosphonomethyl)=amino]methyl]-2,3,4,5,6,7,23,24,25,26,36,37,38,38*a*-tetradecahydro-1*H*,22*H*-23,36-(epiminomethano)-8,11:18,21-dietheno-13,16:31,35-bis(metheno)[1,6,9]oxadiazacyclohexadecino[4,5-*m*][10,2,16]=benzoxadiazacyclotetracosine-26-carboxylic acid

télavancine

acide (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38*aR*)-3-(2-amino-2-oxoéthyl)-10,19-dichloro-44-[[2-*O*-[3-[[2-(décylamino)éthyl]amino]-2,3,6-tridésoxy-3-*C*-méthyl- $\alpha$ -*L*-lyxo-hexopyranosyl]- $\beta$ -D-glucopyranosyl]oxy]-7,22,28,30,32-pentahydroxy-6-[[[(2*R*)-4-méthyl-2-(méthylamino)pentanoyl]amino]-2,5,24,38,39-pentaexo-29-[[[(phosphonométhyl)amino]méthyl]-2,3,4,5,6,7,23,24,25,26,36,37,38,38*a*-tétradécahydro-23,36-(épiminométhano)-8,11:18,21-diéthéno-22*H*-13,16:31,35-diméthéno-1*H*,13*H*]-[1,6,9]oxadiazacyclohexadécino=[4,5-*m*][10,2,16]benzoxadiazacyclotétracosine-26-carboxylique

telavancina

ácido (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38*aR*)-3-(2-amino-2-oxoetil)-10,19-dicloro-44-[[2-*O*-[3-[[2-(decilamino)etil]amino]-2,3,6-tridesoxi-3-*C*-metil- $\alpha$ -*L*-lyxo-hexopiranosil]- $\beta$ -D-glucopiranosil]oxi]-7,22,28,30,32-pentahidroxi-6-[[[(2*R*)-4-metil-2-(metilamino)=pentanoil]amino]-2,5,24,38,39-pentaexo-29-[[[(fosfonometil)amino]=metil]-2,3,4,5,6,7,23,24,25,26,36,37,38,38*a*-tetradecahidro-23,36-(epiminometano)-8,11:18,21-dieteno-22*H*-13,16:31,35-dimeteno-1*H*,13*H*]-[1,6,9]oxadiazaciclohexadecino=[4,5-*m*][10,2,16]benzoxadiazaciclotetracosina-26-carboxílico

C<sub>80</sub>H<sub>106</sub>Cl<sub>2</sub>N<sub>11</sub>O<sub>27</sub>P

**tifuvirtidum**

tifuvirtide


*N*-acetyl-L-tryptophyl-L-glutaminy-L-glutamyl-L-tryptophyl-L-glutamyl-L-glutaminy-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-glutamyl-L-glutaminy-L-alanyl-L-glutaminy-L-isoleucyl-L-glutaminy-L-glutaminy-L-glutamyl-L-lysyl-L-asparagyl-L-glutamyl-L-tyrosyl-L-glutamyl-L-leucyl-L-glutaminy-L-lysyl-L-leucyl-L-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-glutamyl-L-tryptophyl-L-phenylalaninamide

tifuvirtide

acétyl-L-tryptophyl-L-glutaminy-L-glutamyl-L-tryptophyl-L-glutamyl-L-glutaminy-L-lysyl-L-isoleucyl-L-thréonyl-L-alanyl-L-leucyl-L-leucyl-L-glutamyl-L-glutaminy-L-alanyl-L-glutaminy-L-isoleucyl-L-glutaminy-L-glutaminy-L-glutamyl-L-lysyl-L-asparaginy-L-glutamyl-L-tyrosyl-L-glutamyl-L-leucyl-L-glutaminy-L-lysyl-L-leucyl-L-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-séryl-L-leucyl-L-tryptophyl-L-glutamyl-L-tryptophyl-L-phénylalaninamide

tifuvirtida

acetyl-L-triptofil-L-glutaminil-L-glutamil-L-triptofil-L-glutamil-L-glutaminil-L-lisil-L-isoleucil-L-treonil-L-alanil-L-leucil-L-leucil-L-glutamil-L-glutaminil-L-alanil-L-glutaminil-L-isoleucil-L-glutaminil-L-glutaminil-L-glutamil-L-lisil-L-asparaginil-L-glutamil-L-tirosil-L-glutamil-L-leucil-L-glutaminil-L-lisil-L-leucil-L-aspartil-L-lisil-L-triptofil-L-alanil-L-seril-L-leucil-L-triptofil-L-glutamil-L-triptofil-L-fenilalaninamida

C<sub>235</sub>H<sub>341</sub>N<sub>57</sub>O<sub>67</sub>**tilargininum**


tilarginine

*N*<sup>ε</sup>-(methilamidino)-L-ornithine

tilarginine

acide (2*S*)-2-amino-5-(3-méthylguanidino)pentanoïque

tilarginina

*N*<sup>ε</sup>-(metilamidino)-L-ornitinaC<sub>7</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>**topilutamidum**

topilutamide



(2*RS*)-2-hydroxy-2-methyl-*N*-[4-nitro-3-(trifluoromethyl)phenyl]-3-[(trifluoroacetyl)amino]propanamide

topilutamide

(2*RS*)-2-hydroxy-2-méthyl-*N*-[4-nitro-3-(trifluorométhyl)phényl]-3-[(trifluoroacétyl)amino]propanamide

topilutamida

(2*RS*)-2-hidroxi-2-metil-*N*-[4-nitro-3-(trifluorometil)fenil]-3-[(trifluoroacetil)amino]propanamida

**torapsetum**

torapset


42-89-glycoprotein (human clone PMT21:PL85 P-selectin glycoprotein ligand fusion protein with immunoglobulin (human constant region)

torapset

dimère de la protéine de fusion de la [48-proline]glycoprotéine (ligand 1 de la sélectine-P humaine)-(1-48)-peptide avec le peptide de 224 résidus, partie C-terminale de la chaîne lourde de l'immunoglobuline G1 humaine

torapset

dímero de la proteína de fusión de la [48-prolina]glicoproteína (ligando 1 de la selectina-P humana)-(1-48)-péptido con el péptido de 224 residuos, parte C-terminal de la cadena pesada de la inmunoglobulina G1 humana



QATEYFYLDY	DFLPETEPPE
MLRNSTDTP	LTGPGTPEST
TVEPAARPHT	CPPCPAPEAL
GAPSVFLFPP	KPKDTLMISR
TPEVTCVVVD	VSHEDPEVKF
NWYVDGVEVH	NAKTKPREEQ
YNSTYRVVSV	LTVLHQDWLN
GKEYKCKVSN	KALPVPIEKT
ISKAKGQPRE	PQVYTLPPSR
EEMTKNQVSL	TCLVKGFYPS
DIAVEWESNG	QPENNYKTP
PVLDSGDGSFF	LYSKLTVDKS
RWQQGNVFSC	SVMHEALHNN
YTQKSLSLSP	GK

2

**trodusqueminum**

trodusquimine


(24*R*)-3β-([3-([4-[(3-aminopropyl)amino]butyl)amino]propyl]amino)-7α-hydroxy-5α-cholestan-24-yl hydrogen sulfate

trodusquimine

hydrogénosulfate de (24*R*)-3β-[[3-[[4-[(3-aminopropyl)amino]butyl]=amino]propyl]amino]-7α-hydroxy-5α-cholestan-24-yle

trodusquemina

hidrogénosulfato de (24*R*)-3β-[[3-[[4-[(3-aminopropil)amino]butil]=amino]propil]amino]-7α-hidroxi-5α-colestan-24-ilo

$C_{37}H_{72}N_4O_5S$ **vandetanibum**


vandetanib

*N*-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine

vandétanib

*N*-(4-bromo-2-fluorophényl)-6-méthoxy-7-[(1-méthylpipéridin-4-yl)méthoxy]quinazolin-4-amine

vandetanib

*N*-(4-bromo-2-fluorofenil)-7-[(1-metilpiperidin-4-il)metoxi]-6-metoxiquinazolin-4-amina $C_{22}H_{24}BrFN_4O_2$ **vestipitantum**


vestipitant

(2*S*)-*N*-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-*N*-methylpiperazine-1-carboxamide

vestipitant

(+)-(2*S*)-*N*-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-(4-fluoro-2-méthylphényl)-*N*-méthylpipérazine-1-carboxamide

vestipitant

(+)-(2*S*)-*N*-[(1*R*)-1-[3,5-bis(trifluorometil)fenil]etil]-2-(4-fluoro-2-metilfenil)-*N*-metilpiperazina-1-carboxamida $C_{23}H_{24}F_7N_3O$ 

**AMENDMENTS TO PREVIOUS LISTS**  
**MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES**  
**MODIFICACIONES A LAS LISTAS ANTERIORES**

**Recommended International Nonproprietary Names (Rec. INN): List 51**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 51**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 51**  
*(WHO Drug Information, Vol. 18, No. 1, 2004)*

p. 94     **eptoterminum alfa**

eptotermín alfa  
eptotermine alfa  
eptotermína alfa

*replace the graphic formula by:*  
*remplacer la formule développée par:*  
*sustitúyase la fórmula desarrollada por la siguiente:*


STGSKQRSQN	RSKTPKNQEA	LRMANVAENS	SSDQRQACKK
HELYVSFRDL	GWQDWIIAPE	GYAAYCEGE	CAFPLNSYMN
ATNHAIVQTL	VHFINPETVP	KPCCAPTQLN	AISVLYFDDS
SNVILKKYRN	MVVRACGCH		

**Recommended International Nonproprietary Names (Rec. INN): List 52**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 52**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 52**  
*(WHO Drug Information, Vol. 18, No. 3, 2004)*

p. 248     **beminafilum**

beminafil  
béminafil  
beminafilo

*replace the graphic formula by the following:*  
*remplacer la formule développée par la suivante:*  
*sustitúyase la fórmula desarrollada por la siguiente:*



p. 264     **zanolimumabum**

zanolimumab  
zanolimumab  
zanolimumab

*delete the graphic formula*  
*supprimer la formule développée*  
*suprímase la fórmula desarrollada*

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.